---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125331"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:59:54.223365+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q3 revenue up 6% to $115.2M, net income $12.3M vs $3.2M; updates FY guidance

## Summary
- Net revenue $115.2M (+6% YoY); Advanced Wound Care $108.0M (+7%).
- GAAP net income $12.3M ($0.09 diluted EPS) vs $3.2M ($0.02) YoY.
- Adjusted EBITDA $13.4M, down from $16.0M; Non-GAAP operating income $7.1M vs $11.0M.
- Cash $94.9M, net debt $62.1M; FY guidance: rev $455-480M, adj net income $6.7-18.4M.
- CEO cites brand equity and work with policymakers on access solution.

## SEC filing metadata
- accession: 0000950170-24-125331
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017024125331/0000950170-24-125331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017024125331/orgo-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125331
- JSON: https://secwatch.observer/filing/0000950170-24-125331.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125331.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.